Je‐Jung Lee

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 780 citations · Full text

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · Blood · 2017 · 267 citations · Full text

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel et al. · Haematologica · 2018 · 254 citations · Full text

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi et al. · JAMA · 2019 · 244 citations · Full text